These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 14534533)
1. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Shah K; Tang Y; Breakefield X; Weissleder R Oncogene; 2003 Oct; 22(44):6865-72. PubMed ID: 14534533 [TBL] [Abstract][Full Text] [Related]
2. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Shah K; Bureau E; Kim DE; Yang K; Tang Y; Weissleder R; Breakefield XO Ann Neurol; 2005 Jan; 57(1):34-41. PubMed ID: 15622535 [TBL] [Abstract][Full Text] [Related]
3. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [TBL] [Abstract][Full Text] [Related]
4. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Pollack IF; Erff M; Ashkenazi A Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907 [TBL] [Abstract][Full Text] [Related]
6. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Shah K; Tung CH; Breakefield XO; Weissleder R Mol Ther; 2005 Jun; 11(6):926-31. PubMed ID: 15922963 [TBL] [Abstract][Full Text] [Related]
7. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Katz MH; Spivack DE; Takimoto S; Fang B; Burton DW; Moossa AR; Hoffman RM; Bouvet M Ann Surg Oncol; 2003 Aug; 10(7):762-72. PubMed ID: 12900367 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289 [TBL] [Abstract][Full Text] [Related]
9. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Ray P; Tsien R; Gambhir SS Cancer Res; 2007 Apr; 67(7):3085-93. PubMed ID: 17409415 [TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages. Strebel A; Bachmann F; Wernli M; Erb P Int J Cancer; 2002 Aug; 100(6):627-34. PubMed ID: 12209599 [TBL] [Abstract][Full Text] [Related]
11. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708 [TBL] [Abstract][Full Text] [Related]
12. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Griffith TS; Broghammer EL Mol Ther; 2001 Sep; 4(3):257-66. PubMed ID: 11545617 [TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis in glioma cell lines by TRAIL/Apo-2l. Wu M; Das A; Tan Y; Zhu C; Cui T; Wong MC J Neurosci Res; 2000 Aug; 61(4):464-70. PubMed ID: 10931534 [TBL] [Abstract][Full Text] [Related]
14. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667 [TBL] [Abstract][Full Text] [Related]
15. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Fulda S; Wick W; Weller M; Debatin KM Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245 [TBL] [Abstract][Full Text] [Related]
16. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Jacobs AH; Winkeler A; Hartung M; Slack M; Dittmar C; Kummer C; Knoess C; Galldiks N; Vollmar S; Wienhard K; Heiss WD Hum Gene Ther; 2003 Feb; 14(3):277-97. PubMed ID: 12639307 [TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019 [TBL] [Abstract][Full Text] [Related]
18. Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. Aboody-Guterman KS; Pechan PA; Rainov NG; Sena-Esteves M; Jacobs A; Snyder EY; Wild P; Schraner E; Tobler K; Breakefield XO; Fraefel C Neuroreport; 1997 Dec; 8(17):3801-8. PubMed ID: 9427374 [TBL] [Abstract][Full Text] [Related]
19. Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. Naumann U; Waltereit R; Schulz JB; Weller M J Neurooncol; 2003 Jan; 61(1):7-15. PubMed ID: 12587790 [TBL] [Abstract][Full Text] [Related]